Low serum neutrophil count predicts a positive prostate biopsy

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 4, 2012, Pages 386-390

  Fujita, K ^a   Imamura, R ^a   Tanigawa, G ^a   Nakagawa, M ^a   Hayashi, T ^a   Kishimoto, N ^a   Hosomi, M ^a   Yamaguchi, S ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

biopsy; inflammation; neutrophil; prostate

Indexed keywords

C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BASOPHIL; CONTROLLED STUDY; EOSINOPHIL COUNT; HUMAN; HUMAN TISSUE; JAPANESE; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEEDLE BIOPSY; NEUTROPHIL COUNT; ORGAN WEIGHT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

BIOPSY; BLOOD CELL COUNT; C-REACTIVE PROTEIN; HUMANS; KALLIKREINS; MALE; NEUTROPHILS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869229482     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.27     Document Type: Article

References (21)

1. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179 (4): 1587-1592.
2. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98 (8): 529-534. (Pubitemid 43898816)
3. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000; 37 (4): 404-412. (Pubitemid 30157801)
4. Kandirali E, Boran C, Serin E, Semercioz A, Metin A. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 2007; 70 (4): 743-747. (Pubitemid 350030236)
5. Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H, Yamaguchi S. Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol 2011; 185 (5): 1722-1727.
6. Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T et al. Correlation of histological inflammation in needle biopsy specimens with serum prostatespecific antigen levels in men with negative biopsy for prostate cancer. Urology 2000; 55 (6): 892-898. (Pubitemid 30330795)
7. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7 (4): 256-269. (Pubitemid 46486616)
8. Mengus C, Le Magnen C, Trella E, Yousef K, Bubendorf L, Provenzano M et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med 2011; 9: 162.
9. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008; 112 (11): 2377-2383.
10. Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A, Fujisawao M. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/ml. Urology 2008; 72 (6): 1194-1197.
11. Nonomura N, Takayama H, Kawashima A, Mukai M, Nagahara A, Nakai Y et al. Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate. Cancer Sci 2010; 101 (6): 1570-1573.
12. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 2005; 173 (6): 1930-1934. (Pubitemid 40675214)
13. Kato T, Suzuki H, Komiya A, Imamoto T, Naya Y, Tobe T et al. Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer. Int J Urol 2006; 13 (7): 915-919. (Pubitemid 44049918)
14. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012; 60: 199-215.
15. Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One 2010; 5 (1): e8736.
16. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis 2012; 33 (5): 949-955.
17. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L et al. Polarization of tumorassociated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell 2009; 16 (3): 183-194.
18. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16 (1): 25-29. (Pubitemid 43041217)
19. Fukami A, Yamagishi S, Adachi H, Matsui T, Yoshikawa K, Ogata K et al. High white blood cell count and low estimated glomerular filtration rate are independently associated with serum level of monocyte chemoattractant protein-1 in a general population. Clin Cardiol 2011; 34 (3): 189-194.
20. Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP. Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate 2010; 70 (5): 473-481.
21. The Committee for Establishment of the Guidelines on Screening for Prostate Cancer, Association JU. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int J Urol 2010; 17: 830-838.